Editas Medicine, of Cambridge, MA, has hired former hedge fund manager Andrew Hack as its chief financial officer, the company said this morning. Hack was most recently a portfolio manager at New York hedge fund Millennium Management, where he focused on biotechnology, pharmaceutical, and medical device companies. Hack got his start as the co-founder of Reify Corp., a life science company, and later worked on Wall Street, at HealthCor Management, Carlyle-Blue Wave Partners, and the MPM BioEquities Fund. Editas inked a deal in May with Juno Therapeutics—the Seattle biotech that just announced a $1 billion deal of its own with Celgene—to use Editas’ gene editing technology CRISPR-Cas9 on Juno’s T-cell immunotherapy programs.
Author: David Holley
David is the national correspondent at Xconomy. He has spent most of his career covering business of every kind, from breweries in Oregon to investment banks in New York. A native of the Pacific Northwest, David started his career reporting at weekly and daily newspapers, covering murder trials, city council meetings, the expanding startup tech industry in the region, and everything between. He left the West Coast to pursue business journalism in New York, first writing about biotech and then private equity at The Deal. After a stint at Bloomberg News writing about high-yield bonds and leveraged loans, David relocated from New York to Austin, TX.
He graduated from Portland State University.
View all posts by David Holley
